OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
January 02, 2021
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
October 29, 2020
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
September 03, 2020
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.
August 13, 2020
The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.
June 11, 2020
The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
June 10, 2020
Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.
May 01, 2020
Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.
April 30, 2020
Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.